The biggest thing in diabetes headlines of late is Bydureon, the first and only once-a-week drug to help type 2 diabetics keep their sugars in check, which is newly approved by the FDA. Amylin’s stock price is up, and the pharma blogosphere is all abuzz. But if you’re like us, you may be wondering what the really big deal is. New type 2 drugs come out all the time, don’t they?
Well, for one thing,…
The Artificial Pancreas has the potential to become a huge leap forward in diabetes care. As anxious as all of us are to push the boundaries in diabetes technology, we can’t forget the importance of clinical trials; nothing will move forward without real patients ready and willing to strap on the gear and let researchers observe them for hours on end, most of the time in a clinical setting.
That might not seem like the…
Read more »
Like many of you, Allison and I have been spending time reflecting on the past year, and thinking about where this new year might take us.
Turns out, this month’s Diabetes Social Media Advocacy DSMA Blog Carnival asked just that question:
What is the one thing you are looking forward to in 2012? (diabetes related)
It’s hard to pinpoint just one thing, but here’s where the thought process took us both:
Amy’s Answer…
To me,…
We insulin users have long suspected that the carbohydrate counts on packaged food nutrition labels are not particularly accurate. Who’s with me here?
So in the spirit of turning over a new leaf for a new year, we decided to dig into this a little and find out how nutrition labels are made. Warning: we didn’t much like what we discovered.
Did you know that just like with blood glucose result accuracy, the FDA also…
Yesterday marks “a milestone” in the development of new technology to help automate the care and treatment of type 1 diabetes, according to JDRF!
The U.S. Food and Drug Administration unveiled its eagerly awaited Draft Guidance document for research and development of the Artificial Pancreas system, and initial reaction from JDRF — in a press conference held yesterday afternoon — was a mix of jubilation and a more measured response that they remain “guardedly optimistic” about the details…